Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

• Main Authors: Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel, Nicholas J. Short
• Format: Article
• Language: English
• Published: BMC 2021-09-01
• Series: Journal of Hematology & Oncology
• Subjects: Measurable residual disease; Acute myeloid leukemia; Surrogate endpoint
• Online Access: https://doi.org/10.1186/s13045-021-01148-5

Abstract Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in their sensitivity and applicability to individual patients. MRD detected by quantitative polymerase chain reaction, multiparameter flow cytometry, or next-generation sequencing has prognostic implications in various subsets of AML and at various times throughout treatment. While it is overwhelmingly evident that minute levels of remnant disease confer increased risk of relapse and shortened survival, the therapeutic implications of MRD remain less clear. The use of MRD as a guide to selecting the most optimal post-remission therapy, including hematopoietic stem cell transplant or maintenance therapy with hypomethylating agents, small molecule inhibitors, or immunotherapy is an area of active investigation. In addition, whether there are sufficient data to use MRD negativity as a surrogate endpoint in clinical trial development is controversial. In this review, we will critically examine the methods used to detect MRD, its role as a prognostic biomarker, MRD-directed therapeutics, and its potential role as a study endpoint.